Hinge Health price target raised to $65 from $45 at Raymond James

Raymond James raised the firm’s price target on Hinge Health (HNGE) to $65 from $45 and keeps an Outperform rating on the shares. Hinge Health’s Q2 results were well above expectations across the board, and multiple catalysts are still unfolding, the analyst tells investors in a research note. Underlying growth vectors all suggest that above market growth should continue for the foreseeable future, the firm says.